Nyrada Inc – Nyrada Quarterly Activities Report & Appendix 4C

Highlights:
•Brain Injury Program:
-Stroke model study underway with drug well tolerated to date, efficacy results imminent.
-Walter Reed brain injury study scheduled to commence in 3QFY2024.
-GLP studies scheduled to commence in 3QFY2024.
-On track for Phase I Clinical trial 1HFY2025.

•Cholesterol-Lowering Program:
-Low-cost background works continuing to ascertain program pathway.

•Sound financial position:
-R&D tax rebate of $3.54 million received, exceeding forecast.
-Cash position of $4.65 million as at 31 December 2023 – equivalent to 2.98 cents per share.